Hong Kong Pharmaceuticals and Healthcare Report Q4 2017
BMI View: Hong Kong's pharmaceuticals and healthcare sector continues to show potential forunprecedented growth. Apart from its ageing population, the kind of health issues extant in the country, asreported by the Department of Health, will serve as key growth drivers. Though growth potential inpharmaceuticals is limited, healthcare services will play a greater role in ensuring expansion of the sectoras a whole. Developments within pharmaceuticals will be mainly driven by changes to healthcare provisionmodels. For example, the government continues to subsidise citizens who are unable to afford healthcareservices, thus creating increased opportunities for firms in the market.
Headline Expenditure Projections
Pharmaceuticals: HKD9.6bn (USD1.2bn) in 2016 to HKD10.3bn (USD1.3bn) in 2017; +7.1% in localcurrency and 7.2% US dollars terms. Forecast revised due to new data source.
Healthcare: HKD152.4bn (USD19.6bn) in 2016 to HKD163.7bn (USD21.1bn) in 2017; +7.4% in localcurrency and 7.4% in US dollars terms.